In this video, John C. Byrd, MD, a professor at The Ohio State University, discussed a pair of abstracts that looked at the use of ponatinib for Philadelphia chromosome positive ALL and resistant CML.

Christopher Arendt, PhD, head, Oncology Therapeutic Area Unit, Takeda, speaks on efficacy and safety findings of the OPTIC study examining dose optimization of ponatinib in patients with chronic ...